Viant Announces Date of Second Quarter 2025 Financial Results and Conference Call
Second Quarter 2025 Results and Conference Call
Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company's investor relations website at https://investors.viantinc.com.
ABOUT VIANT
Viant Technology Inc. (NASDAQ: DSP) is a leader in AI-powered programmatic advertising, dedicated to driving innovation in digital marketing. Viant's omnichannel platform built for CTV allows marketers to plan, execute and measure their campaigns with unmatched precision and efficiency. With the launch of ViantAI, Viant is building the future of fully autonomous advertising solutions, empowering advertisers to achieve their boldest goals. Viant was recently awarded Best Demand-Side Platform by MarTech Breakthrough, Great Place to Work® certification and received the Business Intelligence Group's AI Excellence Award. Learn more at viantinc.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Order Up! Take a Trip to the Pizzeria with Kraft Mac & Cheese's New Limited-Edition Pizza Flavor
Kraft is delivering one-dollar boxes of its newest flavor straight to fans' doors in as little as fifteen minutes, complete with a pizza delivery box that smells like it's fresh from the oven PITTSBURGH & CHICAGO, July 29, 2025--(BUSINESS WIRE)--Kraft Mac & Cheese is serving up a slice with its newest limited-edition flavor: Pizza. With bold, savory notes of garlic and classic Italian spices, Kraft captures the essence of a classic slice in every bite, bringing pizza-y goodness to its signature mac & cheese. To celebrate the launch, fans in New York City, Chicago, and Detroit – three of the most iconic pizza capitals of the United States – can get Kraft's newest flavor delivered just like a pizza straight to their doorstep in as little as fifteen minutes in a custom Kraft Mac & Cheese pizza delivery box. Fans can order on Gopuff starting Friday, August 1st, while supplies last, as Fridays are the most popular night of the week to order pizza delivery.1 Each delivery box not only looks like it's straight from the neighborhood pizza parlor, but it smells like it too, complete with that fresh-from-the-oven pizza scent wafting out. In addition to the new flavor and custom box, fans' delivery will include packets of red pepper flakes for any spicy pizza lovers who want to customize their Kraft Mac & Cheese. Perhaps the best part, Kraft is offering its new pizza delivery experience for just one dollar, inspired by the recent revival of the cult classic dollar slice. "Pizza is such an iconic food, and we wanted to create something totally out of the (blue) box to introduce the world to our newest limited-edition flavor," says Cheryl Barbee, Communications Director, Kraft Mac & Cheese at The Kraft Heinz Company. "From the scented delivery box to the rapid delivery timing, red pepper flakes, and even our note to the fans which we designed to look like a 'guest check,' we really lean into the sensorial elements of the pizza delivery experience. We know mac & cheese and pizza fans are going to love it, and we can't wait for them to try our newest flavor." Pizza and mac & cheese share more than just cheesy notes. Both are universal favorites that bring people together at the table, shape memories, and inspire people to customize each bite however they please. With back-to-school fast-approaching, people are busier than ever, stocking up on beloved, delicious, and most importantly, convenient bites including delivery pizza and Kraft Mac & Cheese. Now, Kraft Mac & Cheese is delivering double the nostalgic, cheesy goodness in one bold bite, so people no longer have to choose between the classics. Those unable to experience this special delivery can still revel in the delicious new flavor with Kraft Mac & Cheese Pizza flavor now available for purchase on shelves at retailers nationwide, throughout the back-to-school season. To learn more about Kraft's special delivery experience on Gopuff, visit For more information on Kraft Mac & Cheese Pizza flavor and to stay up to date on the latest news and announcements, follow Kraft Mac & Cheese on Instagram @kraft_macandcheese and TikTok @maccheesebykraft. 1Pizza Delivery Insights, CivicScience Survey, 2023 ABOUT THE KRAFT HEINZ COMPANY We are driving transformation at The Kraft Heinz Company (Nasdaq: KHC), inspired by our Purpose, Let's Make Life Delicious. Consumers are at the center of everything we do. With 2024 net sales of approximately $26 billion, we are committed to growing our iconic and emerging food and beverage brands on a global scale. We leverage our scale and agility to unleash the full power of Kraft Heinz across a portfolio of eight consumer-driven product platforms. As global citizens, we're dedicated to making a sustainable, ethical impact while helping feed the world in healthy, responsible ways. Learn more about our journey by visiting or following us on LinkedIn. ABOUT GOPUFF Gopuff, the leader in instant commerce, offers a relevant and affordable assortment of household essentials, groceries, OTC medication, drinks, snacks and more, all brought to customers' doors in as fast as 15 minutes from local micro-fulfillment centers. Founded in 2013 by co-CEOs Rafael Ilishayev and Yakir Gola, Gopuff leverages proprietary technology, national infrastructure and a hyper-local logistics network to offer unrivaled speed, reliability and affordability to customers across the U.S. and U.K. To learn more, visit or follow Gopuff on Facebook, Twitter or Instagram. Download the Gopuff app on iOS and Android. View source version on Contacts ALISON BROD MARKETING COMMUNICATIONS Kraftheinz@ THE KRAFT HEINZ COMPANY Media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
The 3 Things That Matter for CRISPR Therapeutics Now
Key Points CRISPR Therapeutics' gene-editing treatments are highly customized and shockingly expensive. The market is watching to see if the underlying science can be applied to treat many diseases. The company has plenty of money right now, but its expenses could grow quite a bit from here. 10 stocks we like better than CRISPR Therapeutics › Biotechnology outfit CRISPR Therapeutics (NASDAQ: CRSP) isn't a name on many investors' radar -- and understandably so. Its market capitalization is a mere $6 billion. The company remains in the red largely because it's barely got any revenue to speak of. It's not likely to swing to a profit in the immediate future, either. Still, if you've got room in your portfolio for a little more risk paired with above-average upside potential, this is a stock worth adding to your watchlist (if not your portfolio) with three key things in mind. But first things first. What's CRISPR Therapeutics? Although the company was founded back in 2013, most of its time since then has been spent refining the work first done by Jennifer Doudna, Ph.D., and co-founder Emmanuelle Charpentier, Ph.D., who jointly figured out how to "edit" defective genetic code in a strand of DNA. By using a protein called Cas9 to find and remove a damaged portion of a genetic sequence and then replace it using a gene-editing biotechnology based on clustered regularly interspaced short palindromic repeats -- or CRISPR -- medical science is now able to do what was once unthinkable. It's still early days for the science -- very early. In fact, the FDA only made its first-ever approval of a gene-editing therapy in December of 2023. That's Casgevy, for the treatment of sickle cell disease, which was approved in the U.K. only a month earlier. The thing is, Casgevy is CRISPR Therapeutics' treatment, underscoring how well developed this biotech outfit's science is, and perhaps indirectly underscoring the fact that many rival drug developers are still well behind. Casgevy isn't the company's proverbial big Kahuna, however -- it's merely proof that gene editing can be successfully done. The heavy hitters in CRISPR's developmental pipeline are CTX310 for the treatment of certain cardiovascular diseases, and CTX131 and CTX112, both of which are taking aim at cancer using the very same CRISPR science. Although all of these drugs still have years of developmental work ahead of them, again, the underlying gene-editing technology works. Its potential applications are enormous. That's why CRISPR has a dozen or so others in clinical or pre-clinical trials also underway at this time. Three things to watch As time marches on, though, this stock's backstory is evolving from one broadly driven by an idea to one that increasingly hinges on some very specific factors. To this end, here are the three things that matter the most to current and prospective CRISPR Therapeutics shareholders right now -- and for the foreseeable future -- since they'll either drive the stock higher or let it slide into a sell-off. 1. Insurers and patients' acceptance of CRISPR-based medicine's cost While the science of using CRISPR to repair faulty cells is exciting, it's not exactly cheap or easy. See, Casgevy isn't a pill or an injection. It requires a sample of a patient's own blood stem cells to create a completely customized therapy, which is then infused back into that patient after he or she has undergone chemotherapy. All of this care can only be done at one of CRISPR's 65 authorized treatment centers. Total cost? A little over $2 million per patient. That's pretty steep for any therapy, but particularly for sickle cell disease, which at least has a handful of more affordable treatment options. The cost of treating life-threatening cancer is less of a stumbling block, even for insurers that may occasionally see bills nearly this size for even the most conventional of oncology treatment regimens. The price tag of this and any other future CRISPR-based therapy, however, is likely to remain in this ballpark, where payers may well balk. 2. The ongoing development of CTX310 Again, while Casgevy is approved to treat sickle cell disease, it's really more of a proving ground for the other drugs in CRISPR Therapeutics' developmental pipeline. This, of course, includes CTX131 and CTX112, but the company itself is putting the spotlight on CTX310 as a treatment for ANGPTL3 (angiopoietin-like 3), which is often associated with poorly regulated cholesterol, lipids, and triglycerides. If the company can demonstrate its solution is at least as good as (if not better than) alternative cholesterol-fighting drugs, investors might continue to support this stock. This information is coming. The company posted encouraging early results of CTX310's phase 1 clinical trial late last month, and says it intends to offer more detailed data at a healthcare conference scheduled for later in the year. If it's compelling enough, it could tamp down worries over the high cost of any CRISPR-based treatment. 3. Liquidity Finally, you'll want to keep an eye on CRISPR Therapeutics' liquidity, or the amount of cash it has on hand to cover its operating costs while it continues to develop CTX310 at the same time it's looking to expand Casgevy's commercialization. As of the end of the first quarter, CRISPR was sitting on $1.86 billion in cash, which is a lot for a company of this size. It's working through this money pretty quickly, though, shelling out nearly $150 million in operating expenses in Q1 alone. That doesn't include a full quarter's worth of the sort of costs the phase 1 trial of CTX310 is incurring now, or any other trials it starts or expands in the foreseeable future. Continued revenue growth from Casgevy should seemingly help offset some of this spending, even if not all of it. Indeed, the analyst community expects CRISPR's top line to soar from less than $50 million this year to more than $400 million in 2027, even if these same analysts believe the company will still be well in the red then. A few years' worth of losses isn't exactly unusual for a young biotech start-up. CRISPR Therapeutics would still lack much-needed scale even after such growth, though. The money it needs to spend just to get any meaningful degree of traction from Casgevy or maintain its clinical trials could far exceed any conceivable amount of revenue the newly approved drug might produce in the foreseeable future. Don't confuse what CRSP stock is So what's the call? There isn't one -- not this time. Buying or avoiding a stake in CRISPR Therapeutics is entirely up to you, depending on your risk tolerances and your ability to manage such a holding. If you're strictly a buy-and-hold investor, there's probably not enough certainty here yet to latch onto for the long haul. And there may never be. If you've got a speculative side that can tolerate risk in exchange for hype-driven reward, though, you could make a decent bullish case. Just don't confuse the two, or muddy the waters by trying to be both. The last thing you want to do here is talk yourself into a long-term position that requires you to ignore obvious red flags like the three potential ones discussed above. Should you buy stock in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool has a disclosure policy. The 3 Things That Matter for CRISPR Therapeutics Now was originally published by The Motley Fool
Yahoo
22 minutes ago
- Yahoo
US stock futures higher after EU trade deal boost
U.S. stock futures are higher after the broad S&P 500 scored its sixth straight record high close on July 28. It also was the S&P 500's 15th record high close this year. The tech-heavy Nasdaq also closed at an all-time high. Stocks got a boost after the European Union struck a trade deal with the United States over the weekend. The deal included billions of dollars worth of investments by the EU in the United States and a 15% tariff for most European goods entering the United States. Countries that haven't agreed on a trade deal with the United States have until Aug 1 to reach one. Otherwise, President Donald Trump said the baseline global tariff rate will be between 15% and 20%. At 6:10 a.m. ET, futures tied to the blue-chip Dow added 0.15%, while S&P 500 futures rose 0.28% and Nasdaq futures jumped 0.45%. Make or break week Since mid-April, the S&P 500 has surged nearly 28%, the fastest rebound in over 50 years. Now comes the real test, said Chief Investment Officer Gene Goldman at investment management firm Cetera. Stocks will face a triple threat this week that could either justify the recent rally or create headwinds, he said. The first potential threat is earnings, especially from so-called Magnificent Seven influential megacap tech companies Facebook parent Meta, Microsoft, Amazon and Apple. Investors will be looking at whether artificial intelligence spending is slowing at all. AI spending has boosted tech companies this year. The second potential threat is the Federal Reserve policy meeting. "The Fed is likely to hold rates steady in July with dissents from Governors Waller and Bowman, marking the first time two governors have dissented at a meeting since 1993," said Russell Investments' Global Chief Investment Strategist Paul Eitelman. Eitelman expects the next rate cut at the Fed's September meeting. The last potential threat is July's employment report at the end of the week. It's expected to show 102,000 new jobs, down from 147,000 in June and an uptick in the unemployment rate to 4.2% from 4.1%. Company news Procter & Gamble chief executive Jon Moeller will step down from his role and become executive chairman of the company, effective Jan. 1, 2026. He will be replaced by chief operating officer Shailesh Jejurikar. Cadence Design Systems topped analysts' estimates with its second-quarter results and issued positive full-year guidance. Steel producer Nucor missed second-quarter expectations. It also expects current quarter results to be 'nominally lower' than the second-quarter. Appliance maker Whirlpool reported disappointing second-quarter results and offered full-year guidance below analysts' forecasts. Cryptocurrency PayPal launched "Pay with Crypto" to allow consumers to use many types of cryptocurrencies to complete their purchases, and use wallets such as Coinbase and MetaMask. Once the transaction is completed, the payments will automatically convert to fiat or stablecoin. Pay with Crypto will allow companies to accept cross-border payments in cryptocurrencies and lower their costs for accepting such a transaction, PayPal said. Medora Lee is a money, markets, and personal finance reporter at USA TODAY. You can reach her at mjlee@ and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday. This article originally appeared on USA TODAY: US stock futures higher after EU trade deal boost Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
